| Code | CSB-RA025833MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Varisacumab, targeting vascular endothelial growth factor A (VEGFA), a critical regulator of angiogenesis and vascular permeability. VEGFA plays a central role in physiological and pathological blood vessel formation by binding to VEGF receptors on endothelial cells, promoting their proliferation, migration, and survival. Dysregulated VEGFA signaling is implicated in numerous disease states, including solid tumor growth and metastasis, age-related macular degeneration, diabetic retinopathy, and various inflammatory conditions where aberrant neovascularization contributes to pathology.
Varisacumab is a humanized IgG1 monoclonal antibody that neutralizes VEGFA activity by preventing its interaction with cell surface receptors. This biosimilar antibody provides researchers with a well-characterized tool for investigating VEGFA-mediated signaling pathways, studying angiogenesis mechanisms, and exploring anti-angiogenic therapeutic strategies in oncology and ophthalmology research. The recombinant format ensures consistent performance and reproducibility across experimental studies examining VEGF biology and vascular biology applications.
There are currently no reviews for this product.